CardioGRAFT-MC®
Decellularized Pulmonary Patch Graft

Clinical Overview
Decellularized human pulmonary patch used for right side cardiac repair and reconstruction

Applications
Repair of the right ventricular outflow tract for Tetralogy of Fallot, Truncus Arteriosis, Hypoplastic Left Heart Syndrome, Transposition of the Great Arteries, Pulmonary Stenosis/Atresia

Why Use
- Clinical effectiveness – lower potential for reoperation or intervention\(^1\,^2\)
- Patented, validated decellularization and disinfection process that removes ≥99% of donor DNA\(^3\)
- Resists calcification and stenosis\(^2\)
- Allografts most closely resemble native tissue, making them compliant, flexible and easy to handle
- Potentially reduces operating room time and cost by reducing the rate of serious adverse events and reoperations\(^4\)

References
3. LifeNet Health data on file: PQ-07-078
4. CardioGraft-MC (also known as Matracell\(^R\)) Decellularized Cardiac Patch Allograft Cost-Effectiveness Analysis
   Musculoskeletal Clinical Regulatory Advisors, June 2014
### Decellularized Pulmonary Patch Graft

Frozen Storage (40°C - 100°C)/3 year shelf life

<table>
<thead>
<tr>
<th>Description</th>
<th>Size</th>
<th>Order Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thin (branch)</td>
<td>W = 2.5 - 5.0 cm in 0.5 cm increments; L = 3.0 - 8.0 cm in 0.5 cm increments</td>
<td>DPPGN</td>
</tr>
<tr>
<td>Thick (trunk)</td>
<td>W = 2.5 - 5.0 cm in 0.5 cm increments; L = 3.0 - 8.0 cm in 0.5 cm increments</td>
<td>DPPGK</td>
</tr>
</tbody>
</table>